Severe COVID-19
16
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
2 terminated out of 16 trials
71.4%
-15.1% vs benchmark
19%
3 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Effect of Traditional Chinese Medicine of Severe COVID-19
Risk Identification of Long-term Complications
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
Corticosteroids in Severe COVID-19(ASAP-C Study)
Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
Safety and Efficacy of Medications COVID-19
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy